Generate a patentability assessment report for an invention disclosure on CRISPR gene-editing vectors addressing 35 U.S.C. §101 utility rejections and EPC Rule 28(2) exclusions

Generate generate a patentability assessment report for an invention disclosure on crispr gene-editing vectors addressing 35 u.s.c. §101 utility rejections and epc rule 28(2) exclusions for Scientific Research and Development Services industry

Scientific Research and Development Services

Agent Configuration

Login required: You need to sign in to execute this agent.

Click to upload or drag and drop

Allowed: PDF, DOCX, TXT, ZIP

Max size: 50MB

Upload the complete invention disclosure containing technical specifications, experimental data, and implementation details for the CRISPR gene-editing vector, including sequence listings, construct maps, and proof-of-concept results
Select the primary patent office jurisdiction for this patentability assessment, determining specific §101 utility standards and EPC Rule 28(2) exclusions that will be analyzed
Specify the primary therapeutic or research application domain to assess industry-specific patentability standards, safety requirements, and regulatory pathway implications
Indicate the priority claim situation for this disclosure to assess grace periods, public disclosure timelines, and prior art cutoff dates under 35 U.S.C. §102 and Article 54 EPC
Identify the most likely USPTO art unit or EPO technical field to understand examiner background, historical allowance rates, and specific written description requirements for biotech applications
Choose the patent claim strategy specifically tailored to overcome §101 utility challenges and EPC Rule 28(2) exclusions through strategic limitation approaches
List specific competitor patents, patent families, or known blocking IP that will be cross-referenced during §102 novelty and §103 inventive step analysis
Specify the planned FDA or EMA regulatory approval pathway to align patent strategy with regulatory requirements and data exclusivity timelines
Indicate the projected commercialization phase timeline to optimize patent term extension strategies, FDA regulatory exclusivity coordination, and international filing sequences
Specify the technology transfer scenario affecting patent ownership, licensing obligations, and government march-in rights under Bayh-Dole Act or similar national legislation
Define the comprehensive level of analysis required for the patentability assessment, including depth of prior art analysis, regulatory strategy integration, and business recommendations